INT343365

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.04
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0
Pain Relevance 0.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Acsf2) plasma membrane (Gabrd) ligase activity (Acsf2)
lipid metabolic process (Acsf2)
Acsf2 (Rattus norvegicus)
Gabrd (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 10 100.00 Very High Very High Very High
tetrodotoxin 18 88.16 High High
Pyramidal cell 176 63.84 Quite High
Hippocampus 14 11.40 Low Low
agonist 30 5.00 Very Low Very Low Very Low
Action potential 18 5.00 Very Low Very Low Very Low
GABAergic 8 5.00 Very Low Very Low Very Low
Potency 6 5.00 Very Low Very Low Very Low
Nicotine 4 5.00 Very Low Very Low Very Low
withdrawal 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cognitive Disorder 22 5.00 Very Low Very Low Very Low
Brain Injury 6 5.00 Very Low Very Low Very Low
Disease 4 5.00 Very Low Very Low Very Low
Aging 4 5.00 Very Low Very Low Very Low
Toxicity 2 5.00 Very Low Very Low Very Low
Schizophrenia 2 5.00 Very Low Very Low Very Low
Dementia 2 5.00 Very Low Very Low Very Low
Cv General 4 Under Development 2 5.00 Very Low Very Low Very Low
Drug Induced Neurotoxicity 2 5.00 Very Low Very Low Very Low
Decapitation 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the majority of experiments, ACSF contained the following antagonists to inhibit GABAA, AMPA, NMDA, muscarinic ACh and GABAA/glycine receptors, respectively: 20 µM gabazine, 15 µM DNQX, 50 µM AP-5, 10 µM atropine and 40 µM picrotoxin.
ACSF Negative_regulation (inhibit) of GABAA associated with antagonist
1) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2980465 Disease Relevance 0 Pain Relevance 0.30
In the majority of experiments, ACSF contained the following antagonists to inhibit GABAA, AMPA, NMDA, muscarinic ACh and GABAA/glycine receptors, respectively: 20 µM gabazine, 15 µM DNQX, 50 µM AP-5, 10 µM atropine and 40 µM picrotoxin.
ACSF Negative_regulation (inhibit) of GABAA associated with antagonist
2) Confidence 0.02 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2980465 Disease Relevance 0 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox